Academic Journal

The emerging landscape of SGLT2 inhibitors in pediatric populations with kidney diseases: A comprehensive literature review ; Panorama emergente dos inibidores do SGLT2 em populações pediátricas com doenças renais: Revisão da literatura

التفاصيل البيبلوغرافية
العنوان: The emerging landscape of SGLT2 inhibitors in pediatric populations with kidney diseases: A comprehensive literature review ; Panorama emergente dos inibidores do SGLT2 em populações pediátricas com doenças renais: Revisão da literatura
المؤلفون: Freitas, Joana, Machado, Sara Nogueira, Vieira, Beatriz, Monteiro, Sara, Faria, Sameiro, Costa, Teresa, Mota, Conceição
المصدر: NASCER E CRESCER - BIRTH AND GROWTH MEDICAL JOURNAL; Vol. 33 No. 2 (2024); 111-122 ; NASCER E CRESCER - BIRTH AND GROWTH MEDICAL JOURNAL; Vol. 33 N.º 2 (2024); 111-122 ; 2183-9417
بيانات النشر: Unidade Local de Saúde de Santo António
سنة النشر: 2024
المجموعة: SARC - Serviço de Alojamento de Revistas Científicas (RCAAP - Repositório Científico de Acesso Aberto de Portugal)
مصطلحات موضوعية: cardiovascular disease, chronic kidney disease, diabetes mellitus, gliflozin, pediatrics, sodium-glucose co-transporter 2 inhibitor, doença cardiovascular, doença renal crónica, gliflozina, inibidor do co-transportador 2 de sódio e glicose, pediatria
الوصف: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), originally developed as innovative antihyperglycemic agents, have demonstrated significant benefits in improving metabolic markers and protecting the kidneys and heart in patients with or without type 2 diabetes mellitus. The mechanisms behind these unexpected cardiorenal benefits cannot be attributed solely to improved glycemic control. Recent data suggest that metabolic reprogramming plays a role in the development of cardiorenal metabolic disease.Despite the effectiveness of SGLT2i in the management of chronic kidney disease (CKD)-related comorbidities in adults, their use in the pediatric population remains to be validated. The challenge in pediatric CKD lies in the imbalance between the metabolic needs of a growing child and the declining functional capacity of a failing kidney. Developing strategies to address modifiable factors in the progression of kidney disease is critical given the extended lifespan of the pediatric population.SGLT2i have emerged as innovative candidates for the treatment of CKD in children. By improving renal hemodynamic adaptation and mitigating overall CKD complications, these agents have the potential to be a novel therapeutic option for pediatric patients. This review will focus on the current understanding of how SGLT2i may provide cardiorenal protection. ; Os inibidores do cotransportador 2 de sódio e glicose (SGLT2), inicialmente considerados medicamentos antihiperglicémicos inovadores, demonstraram benefícios significativos na melhoria dos marcadores metabólicos e na proteção renal e cardíaca em doentes com ou sem diabetes mellitus tipo 2. Estas vantagens cardiorenais inesperadas não podem ser atribuídas exclusivamente ao controle glicémico melhorado. Dados recentes sugerem que a reprogramação metabólica desempenha um papel no desenvolvimento de doenças metabólicas cardiorenais.Apesar da eficácia dos inibidores do SGLT2 no tratamento de comorbilidades associadas à doença renal crónica (DRC) em adultos, o seu uso na população ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
Relation: https://revistas.rcaap.pt/nascercrescer/article/view/34096/25226; https://revistas.rcaap.pt/nascercrescer/article/view/34096
الاتاحة: https://revistas.rcaap.pt/nascercrescer/article/view/34096
Rights: Direitos de Autor (c) 2024 Joana Freitas ; https://creativecommons.org/licenses/by-nc/4.0
رقم الانضمام: edsbas.506CA2E6
قاعدة البيانات: BASE